Opioids Don’t Ease Disability in Neuropathic Pain
Medications aren't useful in restoring motion, researchers say
January 2016 Briefing – Pharmacy
Here are what the editors at HealthDay consider to be the most important developments in Pharmacy for January 2016. This roundup includes the latest...
Ezetimibe/Simvastatin Ups Clinical Outcomes in IMPROVE-IT
Reduction in total primary end point events, driven by reductions in myocardial infarction, stroke
Severe Reaction to Pneumococcal Vaccines in Patients With CAPS
Severe local, inflammatory reaction triggered in those with cryopyrin-associated periodic syndromes
High Level of Tenofovir Resistance for Those With HIV
Resistance affects almost two-thirds of those taking tenofovir in sub-Sahara Africa
FDA Approves Zepatier for Chronic Hepatitis C
Medication indicated for patients with hepatitis C virus genotypes 1 and 4 infections
n-3 PUFA Tx After AMI Linked to Drop in Death, Recurrent AMI
Treatment linked to reduction in all-cause mortality, recurrent acute MI though 12-month follow-up
Tysabri Impacts Seroconversion in John Cunningham Virus
Over 14.8 months, natalizumab treatment linked to 15.9 percent increase of value in JCV+ patients
Carbamazepine Affects Warfarin Anticoagulation
Carbamazepine co-treatment linked to subtherapeutic anticoagulative effect of warfarin
FDA Approves Halaven for Advanced Liposarcoma
FDA says it's first liposarcoma drug to improve survival
